All
FDA Grants Priority Review to Keytruda for Non-Muscle Invasive Bladder Cancer
December 3rd 2019The FDA has granted a priority review to a supplemental biologics license application (sBLA) for Keytruda (pembrolizumab), an anti-PD-1 immunotherapy, for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC), according to Merck, the drug’s manufacturer.
FDA Grants Priority Review to Durvalumab for Extensive-Stage Small Cell Lung Cancer
December 3rd 2019The FDA accepted a supplemental biologics license application (sBLA) and granted a priority review to Imfinzi (durvalumab) for the treatment of patients with previously untreated extensive-stage small cell lung cancer (SCLC), according to AstraZeneca, the drug’s manufacturer.
FDA Grants Priority Review to Pemigatinib for Cholangiocarcinoma Treatment
December 3rd 2019The FDA has granted a priority review to a new drug application (NDA) for pemigatinib as a treatment for patients with previously treated, locally advanced or metastatic cholangiocarcinoma – a cancer that originates in the bile ducts – with FGFR2 fusions or rearrangements, according to Incyte, the agent’s manufacturer.
What Patients With CLL/SLL Should Know About the FDA's Approval of Calquence
November 28th 2019The Food and Drug Administration’s approval of Calquence (acalabrutinib) for adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma offers an exciting treatment option, according to Dr. John C. Byrd.
Friday Frontline: Cancer Updates, Research and Education on November 22, 2019
November 22nd 2019From plans to sue the School District of Philadelphia over a mesothelioma diagnosis to Dwayne “The Rock” Johnson singing for a 3-year-old with acute lymphoblastic leukemia, here’s what is making headlines in the cancer space this week.